Navigation Links
New drug for hypertension

The National Chemical Laboratory (NCL) and Emcure Pharmaceuticals Ltd, a Pune-based company have jointly come out with a new drug for the treatment of hypertension. Announcing this at a press conference here on Thursday,// NCL director Sivaram and Emcure managing director Satish Mehta said the chirally pure S-Amlodipine, a product of their collaborative research, will be a great boon for the patients suffering from hypertension.

Stating that Emcure is among the first few in the world to introduce this product, they said the company has been granted permission from Drug Controller General of India for the manufacture of both bulk as well as formulations of S-Amlodipine.

Although Amlodipine is a proven therapy for the treatment of hypertension, it is commonly associated with side effects like headache, dizziness, flusing and abdominal pain, they said.But clinical study of S-Amlodipine has shown that none of the patients in the treatment group reported any such side effects, they said adding, NCL has already filed Indian and foreign patent applications. S-Amlodipine is the first of many more chirally pure drugs on which the NCL and Emcure scientists are working, they added.


'"/>




Page: 1

Related medicine news :

1. Preventing white coat hypertension
2. Risk of dementia reduced hypertension drugs
3. An hour of exercise a week cuts hypertension
4. Drug used to treat hypertension effective in countering Migraines
5. Common, cheaper drugs could be used to treat hypertension
6. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
7. Healthy lifestyle reduces the risk of developing hypertension
8. Prehypertension in the Young Leads to Hypertensive Adults
9. Hypertension, Prehypertension in Youngsters Linked With Heart Enlargement
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug for hypertension

Other Medicine Technology:Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 2Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 3Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6